Headache Trials

In this small single-center RCT, adjunctive IV dexamethasone did not reduce 48-h migraine relapse or improve pain, functional recovery, or health-care use in children and adolescents.

IV CGRP triggered typical IIH headache attacks in 71% vs 18% with placebo (P=0.004) and increased ICP pulse amplitude without changing mean ICP, supporting a CGRP-mediated mechanism for IIH headache a...

Is IV fosphenytoin superior to placebo in reducing pain intensity at 120 minutes in patients with acute trigeminal neuralgia exacerbations?

Which treatment strategy—withdrawal, prevention (oral, anti-CGRP, botulinum toxin), education, neurostimulation, or combinations—is most effective at reducing monthly headache days in patients with medication-overuse headache?

Does adding a 28-day prednisone taper to galcanezumab improve outcomes in medication overuse headache compared with either treatment alone?

Is atogepant effective for preventive treatment of chronic migraine in patients with and without acute medication overuse?

Do anti-CGRP monoclonal antibodies effectively prevent attacks in episodic and chronic cluster headache?

Is eptinezumab 400 mg IV every 12 weeks safe, tolerable, and effective for long-term prevention of chronic cluster headache?

Does fremanezumab reduce monthly migraine days and depressive symptoms in patients with migraine and comorbid DSM-5 major depressive disorder?

Is amitriptyline an effective migraine prophylactic, and is the benefit independent of its antidepressant action?

Does eptinezumab combined with brief patient education reduce migraine burden more than placebo plus patient education in adults with chronic migraine and medication-overuse headache?